肺癌免疫治疗的研究进展  

Research Progress of Immunotherapy in Patients with Lung Cancer

作　　者：关丽娜[1] 李世敏[1] 孙文学[1] 孔英君[1] 

机构地区：[1]哈尔滨医科大学附属第一医院呼吸内科,哈尔滨150001

出　　处：《医学综述》2017年第11期2181-2185,共5页Medical Recapitulate

摘　　要：肺癌是造成癌症患者死亡的主要因素之一,而针对肺癌的现有治疗较为局限,治疗效果也不尽人意,预后差。因此,迫切需要相应有效的治疗手段来控制肺癌的发展。常规治疗的应用策略还存在很多不足,故寻求肺癌新的治疗方法尤为重要。目前对于肺癌的靶向治疗及免疫治疗逐渐成为研究热点,包括免疫检查点抑制剂、肿瘤疫苗、过继细胞免疫治疗及细胞因子治疗等,尤其是免疫检查点抑制剂的研究受到广泛重视。因此,可从免疫治疗的方向对肺癌进一步探索。Lung cancer is one of the major factors leading to the death of cancer patients, and the existing treatment for lung cancer is limited, with unsatisfactory treatment effect and poor prognosis. Therefore, there is an urgent need for appropriate effective treatment to control the development of lung cancer. The application strategy of conventional therapy has a lot of unnecessary disadvantages, so finding new treatment of lung cancer is particularly important. At present, targeted therapy and immunotherapy of lung cancer have become a hot research topic, including immunological checkpoint inhibitors, tumor vaccines, adoptive cellular immunotherapy and cytokine therapy, especially the study of immune checkpoint inhibitors have received extensive attention. So the direction of immunotherapy can be further explored for lung cancer.

关 键 词：肺癌 免疫治疗 免疫检查点抑制剂 

分 类 号：R730.51[医药卫生—肿瘤]